BERRY GENOMICS CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.58 CNY | +4.89% |
|
+19.67% | -25.52% |
| 24/04 | Berry Genomics Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 24/04 | Berry Genomics Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 1.37B 189M 15.78B | Sales 2023 | 1.15B 159M 13.28B | Capitalization | 4.07B 563M 46.97B |
|---|---|---|---|---|---|
| Net income 2022 | -255M -35.26M -2.94B | Net income 2023 | -427M -59.04M -4.92B | EV / Sales 2022 | 2.96 x |
| Net Debt 2022 | 10.11M 1.4M 117M | Net cash position 2023 | 48.43M 6.7M 559M | EV / Sales 2023 | 3.49 x |
| P/E ratio 2022 |
-13.9
x | P/E ratio 2023 |
-9.52
x | Employees | 1,438 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.37% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.89% | ||
| 1 week | +19.67% | ||
| Current month | -9.21% | ||
| 1 month | -10.06% | ||
| 3 months | -14.20% | ||
| 6 months | -15.47% | ||
| Current year | -25.52% |
1 week
7.02
8.71
1 month
6.729.82
Current year
5.4013.16
1 year
5.4016.48
3 years
5.4036.37
5 years
5.4098.00
10 years
5.4098.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yang Gao
CEO | Chief Executive Officer | 44 | 14/97/14 |
Dong Wang
DFI | Director of Finance/CFO | 51 | 20/17/20 |
Hong Yan Chen
ADM | Chief Administrative Officer | 38 | 07/20/07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yang Gao
CEO | Chief Executive Officer | 44 | 14/97/14 |
| 48 | - | ||
Dong Wang
DFI | Director of Finance/CFO | 51 | 20/17/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 8.58 | +4.89% | 26 187 960 |
| 26/24/26 | 8.18 | +0.99% | 33,552,280 |
| 25/24/25 | 8.1 | +10.05% | 10,040,090 |
| 24/24/24 | 7.36 | +0.14% | 9,249,201 |
| 23/24/23 | 7.35 | +4.70% | 11,695,900 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Berry Genomics Co Ltd is a company mainly engaged in medical testing related services. The Company's business is comprised of basic scientific research services, medical testing services, testing reagent sales and testing equipment sales. The basic scientific research services business provides the clients with multiple sequencing platforms for testing projects, such as transcriptome sequencing, human whole exome sequencing and whole genome sequencing. The medical testing services business include tumor genetic testing services, genetic disease genetic testing services and reproductive health testing services. The Company sells a range of reagents and equipment, including NextSeq CN500 gene sequencer and general reagents for sequencing reactions.
Calendar
17/05/2024
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.52% | 399M | |
| -16.58% | 8.25B | |
| +41.70% | 3.58B | |
| -35.59% | 2.46B | |
| -7.88% | 2.46B | |
| -8.95% | 2.38B | |
| -4.94% | 1.81B | |
| -18.85% | 1.55B | |
| -38.35% | 1.21B | |
| +6.91% | 1.11B |
- Stock Market
- Equities
- 000710 Stock
